T. Rowe Price Associates
IMVT icon

T. Rowe Price Associates’s Immunovant IMVT Stock Holding History

T. Rowe Price Associates’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.44M Sell
339,607
-553,449
-62% -$14.3M ﹤0.01% 1252
2025
Q4 		$22.7M Buy
893,056
+688,472
+337% +$15.4M ﹤0.01% 1038
2025
Q3 		$3.3M Buy
204,584
+143,470
+235% +$2.32M ﹤0.01% 1536
2025
Q2 		$978K Sell
61,114
-683,430
-92% -$10.3M ﹤0.01% 1999
2025
Q1 		$12.7M Sell
744,544
-171,706
-19% -$3.59M ﹤0.01% 1064
2024
Q4 		$22.7M Sell
916,250
-292,796
-24% -$8.31M ﹤0.01% 968
2024
Q3 		$34.5M Sell
1,209,046
-152,603
-11% -$4.5M ﹤0.01% 858
2024
Q2 		$35.9M Sell
1,361,649
-500,394
-27% -$14.2M ﹤0.01% 816
2024
Q1 		$60.2M Buy
1,862,043
+259,481
+16% +$9.47M 0.01% 678
2023
Q4 		$67.5M Buy
1,602,562
+872,520
+120% +$32.1M 0.01% 622
2023
Q3 		$28M Buy
730,042
+710,514
+3,638% +$16.1M ﹤0.01% 837
2023
Q2 		$371K Sell
19,528
-423,676
-96% -$7.9M ﹤0.01% 2276
2023
Q1 		$6.88M Buy
443,204
+167,205
+61% +$2.9M ﹤0.01% 1118
2022
Q4 		$4.9M Buy
+275,999
New +$3.48M ﹤0.01% 1196
2021
Q4 		– Sell
-22,680
Closed -$197K – 3013
2021
Q3 		$197K Buy
22,680
+5,077
+29% +$45.8K ﹤0.01% 2732
2021
Q2 		$186K Buy
17,603
+345
+2% +$4.82K ﹤0.01% 2745
2021
Q1 		$277K Sell
17,258
-272,730
-94% -$7.19M ﹤0.01% 2591
2020
Q4 		$13.4M Buy
289,988
+84,438
+41% +$3.9M ﹤0.01% 1306
2020
Q3 		$7.23M Buy
+205,550
New +$6.18M ﹤0.01% 1362

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates's IMVT Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Immunovant (IMVT) stake by 62% in Q1 2026, selling an estimated $14.3M and leaving 339,607 shares worth $8.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1252.

T. Rowe Price Associates first reported a position in IMVT in Q3 2020 and has held it in 19 quarters since. The position peaked at $67.5M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • T. Rowe Price Associates held 339,607 shares of Immunovant worth $8.44M as of Q1 2026.
  • T. Rowe Price Associates sold 553,449 Immunovant shares in Q1 2026, an estimated $14.3M.
  • Immunovant made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1252 holding.
  • T. Rowe Price Associates first reported a position in Immunovant in Q3 2020 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Immunovant position peaked at $67.5M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.